Subthreshold yellow laser for fovea-involving diabetic macular edema in a series of patients with good vision: effectiveness and safety of a fovea-sparing technique

Filloy, Alejandro; Chong, Victor; Solé, Eduard

doi:10.1186/s12886-020-01536-4

Cited by 6 publications

(4 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Overall, a worsening of both BCVA and CMT was not observed in any of the cohorts evaluated [ 29 – 42 ]. In particular, a significant CMT decrease and BCVA improvement in two thirds were demonstrated [ 29 – 37 ] and in half of the studies [ 29 , 30 , 33 , 36 , 38 , 40 , 41 ], respectively, whereas a stabilization of these features was described in the remaining cases throughout the entire follow-up [ 31 , 32 , 34 , 35 , 37 – 42 ].…”

Section: Clinical Applicationsmentioning

confidence: 99%

Yellow Subthreshold Micropulse Laser in Retinal Diseases: An In-Depth Analysis and Review of the Literature

et al. 2023

View full text Add to dashboard Cite

Yellow subthreshold micropulse laser (YSML) is a retinal laser capable of inducing a biologic response without causing thermal damage to the targeted tissue. The 577-nm YSML is delivered to the retina abiding by different protocols in which wavelength, power, duration, spot size and number of spots can be properly set to achieve the most effective and safe treatment response in various chorioretinal disorders. The ultrashort trains of power modulate the activation of the retinal pigment epithelium cells and intraretinal cells, such as Müller cells, causing no visible retinal scars. Subthreshold energy delivered by YSML stimulates the production of the heat-shock proteins, highly conserved molecules that protect cells against any sort of stress by blocking apoptotic and inflammatory pathways that cause cell damage. YSML treatment allows resorption of the subretinal fluid in central serous chorioretinopathy and intraretinal fluid in various conditions including diabetic macular edema, postoperative cystoid macular edema and other miscellaneous conditions. YSML also seems to modulate the development and progression of reticular pseudodrusen in dry age-related macular degeneration. The aim of this review is to discuss and summarize the safety and efficacy of YSML treatment in retinal diseases.

show abstract

Section: Clinical Applicationsmentioning

confidence: 99%

Yellow Subthreshold Micropulse Laser in Retinal Diseases: An In-Depth Analysis and Review of the Literature

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Besides the widely used OCT, also other image modalities may be helpful and contribute additional biomarkers. The quantification of short wavelength confocal 450 nm fundus autofluorescence, for example, may be considered as an imaging biomarker of retinal inflammation in DM, but this founding request further investigation of different fluorophores and their topographical distribution in the diabetic retina [ 170 , 171 , 172 , 173 , 174 , 175 , 176 ].…”

Section: Discussion and General Recommendationmentioning

confidence: 99%

The Role of Intravitreal Corticosteroids in the Treatment of DME: Predictive OCT Biomarkers

Munk

Somfai

Smet

et al. 2022

IJMS

View full text Add to dashboard Cite

This work aims to summarize predictive biomarkers to guide treatment choice in DME. Intravitreal anti-VEGF is considered the gold standard treatment for centers involving DME, while intravitreal steroid treatment has been established as a second-line treatment in DME. However, more than 1/3 of the patients do not adequately respond to anti-VEGF treatment despite up to 4-weekly injections. Not surprisingly, insufficient response to anti-VEGF therapy has been linked to low-normal VEGF levels in the serum and aqueous humor. These patients may well benefit from an early switch to intravitreal steroid treatment. In these patients, morphological biomarkers visible in OCT may predict treatment response and guide treatment decisions. Namely, the presence of a large amount of retinal and choroidal hyperreflective foci, disruption of the outer retinal layers and other signs of chronicity such as intraretinal cysts extending into the outer retina and a lower choroidal vascular index are all signs suggestive of a favorable treatment response of steroids compared to anti-VEGF. This paper summarizes predictive biomarkers in DME in order to assist individual treatment decisions in DME. These markers will help to identify DME patients who may benefit from primary dexamethasone treatment or an early switch.

show abstract

“…Предварительно для оценки зон отека и микроаневризм использовали ОКТ-А сканограмму, выполненную в режиме En Face по протоколу HD Angio Retina 6×6 мм на уровне ГСК, наиболее информативно отражающую данные изменения. Критерием включения был ОКТ-подтвержденный ДМО с интраретинальными кистами [17].…”

Section: лазерное воздействие в микроимпульсном режимеunclassified

Application of Micro-Pulse and Continuous Laser Radiation in Navigation Topographically-Oriented Treatment of Focal Diabetic Macular Edema Based

et al. 2022

View full text Add to dashboard Cite

Purpose: to evaluate the clinical efficacy of subthreshold laser treatment of focal DME in continuous and micro-pulse modes using a navigation system based on OCT-A data.Methods. 33 patients (33 eyes) with focal DME were under observation before and after laser treatment. All patients underwent high-resolution OCT-A using the HD Angio Retina 6×6 mm protocol on RTVue-100 XR Avanti (Optovue, USA) and SOLIX (Optovue, USA) devices. The height of edema in the fovea averaged 304.5 ± 5.4 um in the group, in the area of edema outside the fovea — 336.5 ± 7.5 um. The initial best corrected visual acuity (BCVA) was 0.75 ± 0.06. The central retinal sensitivity (CRS) before treatment was 24.10 ± 0.48 dB. The treatment was carried out on the NAVILAS 577S navigation laser system (“OD-OS”, Germany). The results were evaluated within 1, 3 and 6 months after treatment.Results. 1 month after laser treatment, the average CRT in the group was: in the fovea — 294.00 ± 5.38 um, outside the fovea — 318.50 ± 6.44 um. The BCVA increased on average to 0.80 ± 0.06; the CRS to 24.65 ± 0.47 dB. After 3 months, a further decrease in the height of edema was observed (CRT in the fovea was 252.50 ± 2.19 microns, outside the fovea 280.50 ± 3.75 microns). The BCVA increased on average in the group to 0.85 ± 0.06, CRS — 25.50 ± 0.30 dB. After 6 months, the average CRT in the group was: in the fovea — 246.50 ± 1.81 microns, outside the fovea — 273.50 ± 4.56 microns. A stable increase in the BCVA indicators was achieved — 0.85 ± 0.06 and CRS — 26.65 ± 0.16 dB. At the time of 1.3 and 6 months after treatment, an increase in vascular density was observed in the deep vascular complex and the superficial vascular plexus.Conclusion. The preliminary results obtained by us indicate the effectiveness of navigation sub-threshold laser treatment of DME in the micro-pulse and continuous modes, based on targeted topographicallyoriented laser exposure according to OCT angiography.

show abstract

Subthreshold yellow laser for fovea-involving diabetic macular edema in a series of patients with good vision: effectiveness and safety of a fovea-sparing technique

Cited by 6 publications

References 17 publications

Yellow Subthreshold Micropulse Laser in Retinal Diseases: An In-Depth Analysis and Review of the Literature

Yellow Subthreshold Micropulse Laser in Retinal Diseases: An In-Depth Analysis and Review of the Literature

The Role of Intravitreal Corticosteroids in the Treatment of DME: Predictive OCT Biomarkers

Application of Micro-Pulse and Continuous Laser Radiation in Navigation Topographically-Oriented Treatment of Focal Diabetic Macular Edema Based

Contact Info

Product

Resources

About